[go: up one dir, main page]

AU2002241720A1 - Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer - Google Patents

Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

Info

Publication number
AU2002241720A1
AU2002241720A1 AU2002241720A AU4172002A AU2002241720A1 AU 2002241720 A1 AU2002241720 A1 AU 2002241720A1 AU 2002241720 A AU2002241720 A AU 2002241720A AU 4172002 A AU4172002 A AU 4172002A AU 2002241720 A1 AU2002241720 A1 AU 2002241720A1
Authority
AU
Australia
Prior art keywords
kits
assessment
therapy
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241720A
Other languages
English (en)
Inventor
John Lee
James Lillie
Gordon Mills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2002241720A1 publication Critical patent/AU2002241720A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002241720A 2000-11-08 2001-11-08 Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer Abandoned AU2002241720A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24683900P 2000-11-08 2000-11-08
US60/246,839 2000-11-08
PCT/US2001/050489 WO2002046765A2 (fr) 2000-11-08 2001-11-08 Compositions, trousses, et methodes d'identification, d'evaluation, de prevention et de traitement de cancers de l'ovaire

Publications (1)

Publication Number Publication Date
AU2002241720A1 true AU2002241720A1 (en) 2002-06-18

Family

ID=22932445

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241720A Abandoned AU2002241720A1 (en) 2000-11-08 2001-11-08 Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

Country Status (3)

Country Link
US (1) US20020182619A1 (fr)
AU (1) AU2002241720A1 (fr)
WO (1) WO2002046765A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
CA2516591A1 (fr) * 2003-02-26 2004-09-10 Mount Sinai Hospital Dosage a marqueurs multiples utilise pour depister un cancer des ovaires
ES2394799T3 (es) * 2003-12-31 2013-02-05 The Penn State Research Foundation Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario
CN101473041B (zh) * 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
AU2008226587A1 (en) * 2007-03-09 2008-09-18 Tripath Imaging, Inc. HE4 monoclonal antibodies and methods for their use
JP5144742B2 (ja) * 2007-03-29 2013-02-13 フジレビオ ダイアグノスティックス インコーポレイテッド 乳がんの評価のためのhe4の使用
WO2009076598A1 (fr) 2007-12-12 2009-06-18 Children's Hospital & Research Center At Oakland Utilisation de composés de sphingosine insaturée en tant qu'agents chimiothérapeutiques pour le traitement du cancer
RU2600891C2 (ru) * 2010-08-26 2016-10-27 Юниверсити Оф Вашингтон Тру Итс Сентер Фор Коммерсиализейшен Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
EP3249399A1 (fr) * 2011-09-22 2017-11-29 Memorial Sloan-Kettering Cancer Center Détection du cancer ovarien
EP2809801B1 (fr) * 2012-01-31 2018-07-25 Speiser, Paul Diagnostic non invasif du cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
US5871941A (en) * 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
WO1998024935A1 (fr) * 1996-12-06 1998-06-11 Urocor, Inc. DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER
AU6468998A (en) * 1997-03-19 1998-10-12 Board Of Trustees Of The University Of Arkansas, The Compositions and method for the early diagnosis of ovarian cancer
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

Also Published As

Publication number Publication date
WO2002046765A2 (fr) 2002-06-13
WO2002046765A3 (fr) 2003-08-21
US20020182619A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU4592601A (en) Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2074201A (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU2002365166A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU2003230750A1 (en) Compositions and methods for treating cancer
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2002241720A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2596901A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001249317A1 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
AU2002337943A1 (en) Novel compositions and methods for cancer